News Search Results
Sep 16, 2024, 08:43 ET Piramal Pharma's GHG Commitment Validated and Approved by SBTi
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Sep 16, 2024, 08:00 ET Kyverna Therapeutics Announces Leadership Update
functions. Prior to joining Kite in 2020, Mr. Biddle spent a decade at Genentech, where he successfully led the Breast/Gynecology, Skin Cancer and Ophthalmology franchises through multiple launches and line extensions for both large and smaller products including Kadcyla®, Tecentriq®, Erivedge® and Lucentis®.
More news about: Kyverna Therapeutics
Sep 16, 2024, 07:00 ET Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona
Ophthalmology Futures Forum taking place on 18th September in Barcelona, Spain. Details for the presentations
More news about: Nanoscope Therapeutics
Sep 13, 2024, 01:25 ET India brings early Diabetic Retinopathy detection to the last mile with Artificial Intelligence
India. These trials were published in renowned peer-reviewed, high-impact journals such as JAMA Ophthalmology, Nature Eye, and the Indian Journal of Ophthalmology, among others. International publications validating the solution's performance in Poland,
More news about: Remidio Innovative Solutions Pvt Ltd
Sep 12, 2024, 10:03 ET Surgical Microscopes Market Size to Grow USD 1,399.09 Million by 2030 at a CAGR of 8.6% | Valuates Reports
Surgical Microscopes Market By Application (Dentistry, Ent, Gynecology & Urology, Neurosurgery & Spine Surgery, Oncology, Ophthalmology, Plastic And Reconstructive Surgeries), By End-User (Hospitals, Outpatient Facilities), By Price Range (Low-Range, Mid-Range, Premium-Range), :
More news about: Valuates Reports
Sep 12, 2024, 08:00 ET Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences
development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced its participation at key upcoming ophthalmology conferences to discuss the Company's clinical development efforts in
More news about: Stealth BioTherapeutics Inc.
Sep 12, 2024, 08:00 ET ZEISS Redefines Disease Management and Treatment within the ZEISS Retina Workflow
diagnoses and treatment plans efficiently and with good patient outcomes," said Euan S. Thomson, Ph.D., President of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit at ZEISS Medical Technology. "We're excited to showcase our expanding ZEISS Retina
More news about: Carl Zeiss Meditec AG
Sep 12, 2024, 08:00 ET ZEISS Redefines Disease Management and Treatment within the ZEISS Retina Workflow
diagnoses and treatment plans efficiently and with good patient outcomes," said Euan S. Thomson, Ph.D., President of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit at ZEISS Medical Technology. "We're excited to showcase our expanding ZEISS Retina
More news about: Carl Zeiss Meditec AG
Sep 12, 2024, 04:32 ET Rising Demand for Microelectronic Medical Implants Propels Market Growth at 11.7% CAGR Through 2029
defibrillators, neurostimulators, hearing implants, ocular implants, and others, and applications including cardiology, neurology, audiology, and ophthalmology. The analysis covers regional markets in North America, Europe, Asia-Pacific,
More news about: BCC Research LLC
Sep 11, 2024, 20:00 ET Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical trial results for mazdutide, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon
More news about: Innovent Biologics
Sep 10, 2024, 20:00 ET Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced the presentation of Phase 1 clinical data (ClinicalTrials.gov, NCT04085185) for IBI363 (first-in-class PD-1/IL-2α-bias
More news about: Innovent Biologics
Sep 10, 2024, 13:00 ET Adcentrx Therapeutics Announces Formation of Scientific Advisory Board
President of Drug Discovery at Pfizer Global Research & Development, leading research initiatives across oncology, virology, diabetes, and ophthalmology at the La Jolla site. Dr. Varney holds a Ph.D. in Organic Synthesis from the California
More news about: Adcentrx Therapeutics
Sep 10, 2024, 09:00 ET Zack Dvey-Aharon, Co-Founder and CEO of AEYE Health, Named to TIME's 2024 Annual List of the TIME 100 AI
reimbursement, utilizing CPT code 92229, further increasing incentives for the technology's rapid adoption. Dr. Sean Ianchulev, Professor of Ophthalmology at New York Eye and Ear of Mount Sinai, remarked: "I'm proud to work with Dr. Dvey-Aharon and extend my congratulations
More news about: AEYE Health
Sep 10, 2024, 08:34 ET Matter Brands Unveils New Sustainable iPhone 16 Accessories from Gadget Guard and Atom Studios
world-class team of eye doctors, engineers, and scientists with decades of experience in electronics, display materials, light management, optometry, and ophthalmology. Learn more at
More news about: Matter Brands
Sep 10, 2024, 08:01 ET ZEISS to license CREAL's technology to create a digital vision care platform
inSights Q1 2002 report", The Vision Council's[2] Padmaja Sankaridurg, et al, "Impact of Myopia," ARVO Journals, Investigative Ophthalmology & Visual Science, Vol.62, 2, April 2021 About CREAL CREAL is a display technology startup
More news about: CREAL
Sep 10, 2024, 07:00 ET InMode Announces Share Repurchase Program of Up to 7.68 Million Shares
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode LTD
Sep 09, 2024, 23:42 ET The World's First Whole-Eye & Partial-Face Transplant Recipient Achieves Remarkable Recovery, with Viable Eye One Year After Landmark Surgery
Ophthalmology and
More news about: NYU Langone Health
Sep 09, 2024, 20:00 ET Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces an oral presentation of updated results from a pivotal Phase 2 clinical trial of Dupert®（fulzerasib）for
More news about: Innovent Biologics
Sep 09, 2024, 15:05 ET OcuDyne Announces Positive Results for the OPTiC System™ 6-Month Clinical Trial in the Treatment of Geographic Atrophy
demonstrated.Interim data from this clinical trial were accepted and presented at the annual Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, WA in May 2024. Final data is now available, is supporting
More news about: Ocudyne, Inc.
Sep 09, 2024, 09:31 ET Star Health Insurance Launches India's First Insurance Policy in Braille
million people in India, or 2.5% of the population, are visually impaired. A 2022 study by the Indian Journal of Ophthalmology estimated that vision impairment causes an economic loss of INR 646 billion in productivity, with a per capita loss of INR 9,192. This policy addresses
More news about: Star Health and Allied Insurance
Sep 09, 2024, 03:00 ET Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves
More news about: Formosa Pharmaceuticals Inc.,
Sep 07, 2024, 11:16 ET Honorable Governor of Maharashtra Shri C.P. Radhakrishnan joins Samvatsari celebrations in pious presence of Pujya Gurudevshri Rakeshji
animals was also announced. This hospital will serve as an advanced model for animal care offering facilities ranging from oncology, orthopedics, ophthalmology, cardiology, pathology lab, dental care to general surgery and specialised surgery. Thus, the Paryushan festival celebrated in the presence
More news about: Shrimad Rajchandra Mission
Sep 06, 2024, 09:00 ET ZEISS Leads IMTS Visitors on a Journey to Discover their Superforce
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: Carl Zeiss Industrial Quality Solutions, LLC
Sep 06, 2024, 08:48 ET Ophthalmology Innovator Joins NYU Langone Health as Chief of Oculoplastics
Kathryn A. Colby, MD, PhD, the Elisabeth J. Cohen, MD, Professor of Ophthalmology, and chair of the Department of Ophthalmology. "Her surgical acumen, dedication to patients, and ability to think outside the box to enhance care and quality are assets
More news about: NYU Langone Health
Sep 06, 2024, 02:30 ET Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain
generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Moebius